New and Effective Treatment of Experimentally Induced Venous Thrombosis with Anti-inflammatory rPSGL-Ig

Summary

Background

P-selectin antagonism decreases thrombosis and inflammation in animal models of venous thrombosis (VT) prophylaxis. This study defines results using a P-selectin receptor antagonist for VT treatment.

Methods

Eight juvenile baboons underwent 6 h of iliofemoral venous stasis to produce an occlusive VT. Two days later, animals were treated for 14 days with rPSGL-Ig, 4 mg/kg (n3), LMWH (n2) or saline (n3) and treatment continued weekly (rPSGL-Ig) or daily (LMWH, saline). The animals were examined and sacrificed 14 days after treatment initiation (n4) or on day 90 (n4).

Results

Percent spontaneous vein reopening revealed a significant increase (p <0.05) in the proximal iliac vein in rPSGL-Ig and LMWH animals compared to controls (62%, 70% vs 8%), without differences in inflammation. No anticoagulation, thrombocytopenia, or wound complications were found in rPSGL-Ig animals. At 90 days, recanalization with iliac vein valve competence was found in treated animals.

Conclusion

rPSGLIg successfully treated established VT without anticoagulation.

Keywords

Venous thrombosis - rPSGL-Ig - P-selectin - inflammation - recanalization

• References

• 1 Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
• 2 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
• 3 van Den Belt AGM, Prins MH, Lensing AWA, Castro AA, Clark OAC, Atallah AN, Burihan E. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systemic Reviews [computer file]. 2001 Issue 4.
• 4 Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Brown SL, Wrobleski SK, Burdick MD, Anderson DC, Greenfield LJ. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 1997; 25: 816-28.
• 5 Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrobleski SK, Londy FJ, Kadell AM, Brown SL, Henke PK, Greenfield LJ. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg 2000; 31: 309-24.
• 6 Myers Jr DD, Schaub R, Wrobleski SK, Londy FJ, Fex BA, Chapman AM, Greenfield LJ, Wakefield TW. P-Selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost 2001; 85: 423-9.
• 7 Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
• 8 Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson DC, Shebuski RJ. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharm & Exp Ther 1995; 275: 941-9.
• 9 Kumar A, Villani MP, Patel UK, Keith Jr JC, Schaub RG. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999; 99: 1363-9.
• 10 Zhang H, Schaub RG, Keith JC, Kumar A. A recombinant soluble P-selectin glycoprotein ligand-1-chimera has a thrombolytic effect in a rat model of thrombosis. JACC. 2000 35. 280 (Abstract) IIII – 42.
• 11 Feingold HM, Pivacek LE, Melaragno AJ, Valeri CR. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res 1986; 47: 2197-9.
• 12 Kelly CA, Gleiser CA. Selected coagulation reference values for adult and juvenile baboons. Lab Animal Sci 1986; 36: 173-5.
• 13 Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41: 65-76.
• 14 Londy FJ, Kadell AM, Wrobleski SK, Prince RM, Strieter RM, Wakefield TW. Detection of perivenous inflammation in a rat model of venous thrombosis using MRV. J Invest Surg 1999; 12: 151-6.
• 15 Fowlkes JB, Strieter RM, Downing LJ, Brown SL, Saluja A, Salles-Cunha S, Kadell AM, Wrobleski SK, Wakefield TW. Ultrasound echogenicity in experimental venous thrombosis. Ultrasound Med Biol 1998; 24: 1175-82.
• 16 Zajkowski PJ, Fex BA, Wrobleski SK, Myers DD, Wakefield TW. Tissue doppler imaging for diagnosis of deep vein thrombosis. Ultrasound Today 2001; 06: 3-12.
• 17 Downing LJ, Strieter RM, Kadell AM, Wilke CA, Austin JC, Hare BD, Burdick MD, Greenfield LJ, Wakefield TW. IL-10 regulates thrombusinduced vein wall inflammation and thrombosis. J Immunology 1998; 161: 1471-76.
• 18 Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kundel SL, Greenfield LJ. Venous thrombosisassociated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 258-68.
• 19 Coon WW, Willis 3d PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973; 48: 839-46.
• 20 Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worchester DVT Study. Arch Int Med 1991; 151: 933-8.
• 21 Peterson KL. Acute pulmonary thromboembolism: has its evolution been redefined?. Circulation 1999; 99: 1280-3.
• 22 Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Hemostasis 1998; 28 (suppl) 3: 8-16.
• 23 Hull R, Delomore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
• 24 Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 02: 515-8.
• 25 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.
• 26 Lensing AW, Prandoni P, Prins MH, Buller HR. Deep-vein thrombosis. Lancet 1999; 353: 479-85.
• 27 Schiele F, Lindgaerde F, Ericksson H, Bassand JP, Wallmark A, Hansson PO, Grollier G, Sjo M, Moia M, Camez A, Smyth V, Walker M. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. Internationa. Multicentre Hirudin Study Group. Thromb Haemost 1997; 77 (05) 834-8.
• 28 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Int Med 1996; 125 (01) 1-7.
• 29 Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of lowmolecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-31.
• 30 Elliott CG. Thrombolytic therapy. In: Venous Thromboembolism: An Evidence-Based Atlas. Hull RD, Raskob GE, Pineo G. Armonk NY: Futura; 1996: 255-63.
• 31 Wakefield TW, Strieter RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thombosis: a new insight. Cardiovascular Surgery 1997; 05 (01) 6-15.
• 32 Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA, Burdick MD, Wrobleski SK, Phillips ML, Paulson JC, Anderson DC, Greenfield J. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res 1996; 64: 26-31.
• 33 Henke PK, DeBrunye LA, Strieter RM, Bromberg JS, Prince M, Kadell AM, Sarkar M, Londy F, Wakefield TW. Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. J Immunology 2000; 164: 2131-41.
• 34 Myers D, Hawley A, Farris DM, Wrobleski SK, Strieter RM, Wakefield TW. Venous thrombosis inflammation in the mouse is influenced by selectins and Interleukin 10, read before the 13th annual meeting of the American Venous Forum, Fort Myers, Florida, February 22-25, 2001 (poster).
• 35 Myers D, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolmon L, Knibbs R, Strieter R, Wakefield T. Selectins and interleukin-10 influence acute thrombus formation in a mouse model of venous thrombosis. Thromb Haemost. (Suppl) July, 2001 (Abstract #OC1001).
• 36 Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney: Inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99 (11) 2682-90.
• 37 McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 485-91.
• 38 Theoret JF, Kumar A, Latour J-G, Merhi Y. Mechanisms of platelet binding to neutrophils in contact with damaged arterial surfaces under flow conditions. Circulation. 1998 98. (17): I-241, #1251 (Abstract).
• 39 Lefer AM, Campbell N, Scalia R, Lefer DJ. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusions: role of selectins. Circulation 1998; 98: 1322-8.
• 40 Rauch U, Bonderman D, Bohrmann B, Badiman JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-5.
• 41 Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000; 95 (04) 1317-23.
• 42 Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-22.
• 43 Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803-14.
• 44 Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta3-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: Correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation 2001; 103: 2501-7.
• 45 Eppihimer MJ, Schaub RG. P-selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler Thromb Vasc Biol 2000; 20: 2483-8.
• 46 Humphries J, McGuinness CL, Smith A, Waltham M, Poston R, Burnand KG. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999; 30: 894-900.
• 47 Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97: 13835-40.
• 48 Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eshwege V, Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-55.
• 49 Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 23111-8.
• 50 Celi A, Pelligrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-71.
• 51 Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
• 52 Swords NA, Tracy PB, Mann KG. Intact platelet membranes, not plateletreleased microvesicles, support the procoagulant activity of adherent platelets. Arteriosclerosis Thromb 1993; 13: 1613-22.
• 53 Kirchhofer D, Tschopp TB, Steiner B, Baumgartner HR. Role of collagenadherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995; 86: 3815-22.
• 54 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: The molecular basis of granule secretion, signaling, and cell adhesion. Thromb Haemost 2001; 86: 214-21.
• 55 Jankowski M, Arnout J, Vermylen J, Hoylaerts MF. Thrombin generation in whole blood depends on platelet-monocyte interactions. Thromb Haemost. (Suppl) July, 2001 (Abstract #P2715).
• 56 Appleby JA, Lamb DJ, Li N, Wright JR, Chapman P, Farndale R, Goodall AH. Monocyte tissue factor expression: The role of platelets. Thromb Haemost. (Suppl) July, 2001 (Abstract #P2703).
• 57 Inwald DP, Peters MJ, Banfield C, Callard RE, Klein NJ. Human platelets express functional CD40: A novel mechanism for platelet activation. Thromb Haemost. (Suppl) July, 2001 (Abstract #P2676).
• 58 See-Tho K, Harris Jr EJ. Thrombosis with outflow obstruction delays thrombolysis and results in chronic wall thickening of rat veins. J Vasc Surg 1998; 28: 115-23.
• 59 Prandoni P, Lensing AWA, Prins MH, Simioni P, Bagatella P, Tormene D, Frulla M, Mosena L, Marchiori A, Girolami A. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Thromb Haemost. (Suppl) July, 2001 (Abstract #OC851).
• 60 Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.